Bavarian Nordic A/S: Vaccines for infectious diseases and oncology. Recently won FDA approval of JYNNEOS for prevention of smallpox & monkeypox, including in high-risk, immunocompromised populations. Also included in its portfolio of wholly-owned and Big Pharma-partnered products, is first broad spectrum vaccine in development for RSV—MVA-BN-RSV—which successfully concluded Ph 2 development, with a Ph 3 trial anticipated to start in 2020. Other vaccine candidates include Ebola, HPV, HBV and HIV, which are being developed through strategic partnership with Janssen. The Company is also advancing vaccine candidate for solid tumors including chordoma -- a rare bone tumor that develops along the spine for which there is currently no available treatment options.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III, Phase l or ll
Disease Space
Immunotherapy, Infectious Disease, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Vaccine
Website:
Profiles:
Address:
Hejreskovvej 10A
Kvistgaard, 3490
Denmark

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.